

Remarks/Arguments


Applicants have amended the specification to provide the priority claim. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

Applicants also hereby submit a sequence listing in hard copy and computer readable form. I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with the 37 C.F.R. §1.821(c) and (e), respectively are the same.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101278-1P US.

Respectfully submitted,



Name: Christine McCormack
Dated: May 11, 2006
Reg. No.: L0065
Phone No.: 1 781 839 4693

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451